Liprolog

Insulin Lispro, the active ingredient in Liprolog, is a fast‑acting insulin analog presented as an injectable solution for subcutaneous and intravenous use. It is used to lower blood glucose levels in patients with diabetes mellitus, providing rapid post‑prandial control. GNH USA supplies Liprolog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog (Insulin Lispro) is a rapid‑acting insulin analog used in the management of diabetes mellitus and related glucose‑control strategies. - Type 1 diabetes mellitus: provides rapid post‑prandial glucose reduction. - Type 2 diabetes mellitus: helps control mealtime glucose excursions. - Insulin pump therapy: serves as a fast‑acting bolus insulin for continuous subcutaneous insulin infusion devices.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Localized allergic reactions: mild rash or urticaria at the site.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological impairment requiring immediate assistance. - Anaphylaxis: systemic allergic reaction with airway compromise. - Hypokalemia: low serum potassium levels, particularly with high doses. - Edema: peripheral swelling due to fluid retention. - Serum insulin antibodies: may alter insulin action. - Urticaria or angioedema: widespread hives or swelling.

When using Liprolog, consider the following precautions: - Dose adjustment: tailor insulin dose based on frequent blood glucose monitoring. - Hypoglycemia risk: educate patients on recognizing and treating low glucose episodes. - Renal impairment: monitor renal function and adjust dose as needed. - Hepatic impairment: use with caution and observe for altered glucose control. - Pregnancy and lactation: only use if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liprolog may interact with several medications; awareness of these interactions helps maintain safe glucose control. Major Interactions (Avoid): - Concurrent insulin products: risk of additive hypoglycemia. - Sulfonylureas or meglitinides: may cause severe hypoglycemia when combined. - Beta‑blockers: can mask hypoglycemia symptoms. Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics: can increase blood glucose, requiring dose adjustments. - Systemic corticosteroids: raise glucose levels, potentially necessitating higher insulin doses.